Archon Biosciences, a biotech startup utilizing AI to design innovative biomolecules, has secured $20 million in seed funding. The company aims to revolutionize antibody treatments by using specially crafted protein “cages” to amplify their effects, creating new possibilities in drug development.
One of the key features of Archon’s antibody cages (AbCs) is their ability to enhance the effectiveness of antibodies by providing a scaffold for modification and multiplication. By grouping antibodies together, the chances of binding to a target protein are significantly improved, potentially leading to more accurate assessments of medication efficacy.
Led by co-founder and CEO James Lazarovits, Archon leverages a proprietary protein design platform developed in collaboration with Baker Lab at the University of Washington. The company’s technology, which builds on generative protein creation tools, could have a wide range of applications in biologics development.
The $20 million funding round was led by Madrona Ventures, with support from various investors. Based in Seattle, Archon is set to make a significant impact in the biotech industry.
